The effects of low dose
melatonin therapy on sleep behavior and serum
melatonin levels were studied in
Angelman syndrome (AS) children suffering from
insomnia. 24-hour motor activity was monitored in 13 AS children (age 2-10 yr) in their home environments for 7 days prior to
melatonin treatment and for 5 days during which a 0.3 mg dose of
melatonin was administered daily 0.5-1 hour before the patient's habitual bedtime. Blood samples were with-drawn at hourly intervals over two 21-hour periods in order to measure individual endogenous serum
melatonin levels and the levels induced by
melatonin treatment. Actigraphic recording of motor activity, confirmed by parents' reports, showed a significant improvement in the patients' nocturnal sleep pattern as a result of
melatonin treatment. Analysis of the group data revealed a significant decrease in motor activity during the total sleep period following
melatonin treatment, and an increase in the duration of the total sleep period. Endogenous peak nocturnal
melatonin values ranged from 19 to 177 pg/ml. The administration of
melatonin elevated peak serum
hormone levels to 128-2800 pg/ml in children of different ages and body mass. These data suggest that a moderate increase in circulating
melatonin levels significantly reduces motor activity during the sleep period in
Angelman syndrome children, and promotes sleep.